Using a population-based observational cohort study to address difficult comparative effectiveness research questions: the CEASAR study
Daniel A. Barocas(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center), Vivien W. Chen(Louisiana State University Health Sciences Center New Orleans), Tatsuki Koyama(Vanderbilt University Medical Center), Sherrie H. Kaplan(University of California, Irvine), Sheldon Greenfield(University of California, Irvine), Alicia K. Morgans(Dana-Farber Cancer Institute), Lisa E. Paddock(Rutgers, The State University of New Jersey), Sharon Phillips(Vanderbilt University Medical Center), Matthew R. Cooperberg(University of California, San Francisco), Ann S. Hamilton(University of Southern California), Karen E. Hoffman(The University of Texas MD Anderson Cancer Center), Xiao Wu(National Center for Chronic Disease Prevention and Health Promotion), John J. Graff(Arbor Research Collaborative for Health), Antoinette M. Stroup(Rutgers, The State University of New Jersey), Matthew J. Resnick(Vanderbilt University Medical Center), Michael Goodman(Emory University)
Cited by 71
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Annual Report to the Nation on the Status of Cancer, 1975–2002, Featuring Population-Based Trends in Cancer Treatment
|JNCI Journal of the National Cancer Institute|2005|954